Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpes.

Farassati F, Pan W, Yamoutpour F, Henke S, Piedra M, Frahm S, Al-Tawil S, Mangrum WI, Parada LF, Rabkin SD, Martuza RL, Kurtz A.

Am J Pathol. 2008 Dec;173(6):1861-72. doi: 10.2353/ajpath.2008.080376. Epub 2008 Nov 6.

2.

Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants.

Mahller YY, Rangwala F, Ratner N, Cripe TP.

Pediatr Blood Cancer. 2006 Jun;46(7):745-54.

PMID:
16124003
3.

Transcription factors down-stream of Ras as molecular indicators for targeting malignancies with oncolytic herpes virus.

Esfandyari T, Tefferi A, Szmidt A, Alain T, Zwolak P, Lasho T, Lee PW, Farassati F.

Mol Oncol. 2009 Dec;3(5-6):464-8. doi: 10.1016/j.molonc.2009.07.002. Epub 2009 Jul 28.

4.

Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.

Ambrosini G, Cheema HS, Seelman S, Teed A, Sambol EB, Singer S, Schwartz GK.

Mol Cancer Ther. 2008 Apr;7(4):890-6. doi: 10.1158/1535-7163.MCT-07-0518.

5.

Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model.

Mahller YY, Vaikunth SS, Currier MA, Miller SJ, Ripberger MC, Hsu YH, Mehrian-Shai R, Collins MH, Crombleholme TM, Ratner N, Cripe TP.

Mol Ther. 2007 Feb;15(2):279-86.

6.

Overactivation of Ras signaling pathway in CD133+ MPNST cells.

Borrego-Diaz E, Terai K, Lialyte K, Wise AL, Esfandyari T, Behbod F, Mautner VF, Spyra M, Taylor S, Parada LF, Upadhyaya M, Farassati F.

J Neurooncol. 2012 Jul;108(3):423-34. doi: 10.1007/s11060-012-0852-1. Epub 2012 Apr 8.

PMID:
22484909
7.

Ral overactivation in malignant peripheral nerve sheath tumors.

Bodempudi V, Yamoutpoor F, Pan W, Dudek AZ, Esfandyari T, Piedra M, Babovick-Vuksanovic D, Woo RA, Mautner VF, Kluwe L, Clapp DW, De Vries GH, Thomas SL, Kurtz A, Parada LF, Farassati F.

Mol Cell Biol. 2009 Jul;29(14):3964-74. doi: 10.1128/MCB.01153-08. Epub 2009 May 4.

8.

PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.

Perrone F, Da Riva L, Orsenigo M, Losa M, Jocollè G, Millefanti C, Pastore E, Gronchi A, Pierotti MA, Pilotti S.

Neuro Oncol. 2009 Dec;11(6):725-36. doi: 10.1215/15228517-2009-003.

9.

NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Park HJ, Lee SJ, Sohn YB, Jin HS, Han JH, Kim YB, Yim H, Jeong SY.

Int J Oncol. 2013 Feb;42(2):657-66. doi: 10.3892/ijo.2012.1751. Epub 2012 Dec 24.

PMID:
23292448
10.

Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1.

Farassati F, Yang AD, Lee PW.

Nat Cell Biol. 2001 Aug;3(8):745-50.

PMID:
11483960
11.

Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors.

Maldonado AR, Klanke C, Jegga AG, Aronow BJ, Mahller YY, Cripe TP, Crombleholme TM.

J Gene Med. 2010 Jul;12(7):613-23. doi: 10.1002/jgm.1479.

PMID:
20603890
12.

Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines.

Jackson JD, McMorris AM, Roth JC, Coleman JM, Whitley RJ, Gillespie GY, Carroll SL, Markert JM, Cassady KA.

Gene Ther. 2014 Nov;21(11):984-90. doi: 10.1038/gt.2014.72. Epub 2014 Aug 14.

13.

Utilizing ras signaling pathway to direct selective replication of herpes simplex virus-1.

Pan W, Bodempudi V, Esfandyari T, Farassati F.

PLoS One. 2009 Aug 4;4(8):e6514. doi: 10.1371/journal.pone.0006514.

14.

Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity.

Cuddington BP, Mossman KL.

J Virol. 2014 Jun;88(12):6885-95. doi: 10.1128/JVI.00849-14. Epub 2014 Apr 2.

15.

Molecular analysis of human cancer cells infected by an oncolytic HSV-1 reveals multiple upregulated cellular genes and a role for SOCS1 in virus replication.

Mahller YY, Sakthivel B, Baird WH, Aronow BJ, Hsu YH, Cripe TP, Mehrian-Shai R.

Cancer Gene Ther. 2008 Nov;15(11):733-41. doi: 10.1038/cgt.2008.40. Epub 2008 Jun 13.

16.

The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors.

Kraniak JM, Sun D, Mattingly RR, Reiners JJ Jr, Tainsky MA.

Mol Cell Biochem. 2010 Nov;344(1-2):267-76. doi: 10.1007/s11010-010-0551-1. Epub 2010 Aug 1.

17.

Classic Ras Proteins Promote Proliferation and Survival via Distinct Phosphoproteome Alterations in Neurofibromin-Null Malignant Peripheral Nerve Sheath Tumor Cells.

Brossier NM, Prechtl AM, Longo JF, Barnes S, Wilson LS, Byer SJ, Brosius SN, Carroll SL.

J Neuropathol Exp Neurol. 2015 Jun;74(6):568-86. doi: 10.1097/NEN.0000000000000201.

18.

Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.

Antoszczyk S, Spyra M, Mautner VF, Kurtz A, Stemmer-Rachamimov AO, Martuza RL, Rabkin SD.

Neuro Oncol. 2014 Aug;16(8):1057-66. doi: 10.1093/neuonc/not317. Epub 2014 Jan 26.

19.

Oncolytic measles virus as a novel therapy for malignant peripheral nerve sheath tumors.

Deyle DR, Escobar DZ, Peng KW, Babovic-Vuksanovic D.

Gene. 2015 Jul 1;565(1):140-5. doi: 10.1016/j.gene.2015.04.001. Epub 2015 Apr 2.

PMID:
25843626
20.

Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.

Patel AV, Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, Aronow BJ, Perentesis JP, Serra E, Cripe TP, Miller SJ, Ratner N.

Clin Cancer Res. 2012 Sep 15;18(18):5020-30. doi: 10.1158/1078-0432.CCR-12-1072. Epub 2012 Jul 18.

Supplemental Content

Support Center